Short Interest In CTI BioPharma Drops 28.7%

The most recent short interest data has been released by the NASDAQ for the 05/30/2014 settlement date, which shows a 3,995,666 share decrease in total short interest for CTI BioPharma Corp (CTIC), to 9,913,697, a decrease of 28.73% since 05/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for CTIC at the 05/30/2014 settlement increased to 2,709,970, as compared to 2,007,413 at the 05/15/2014 report. That brought "days to cover" down to 3.66, a 47.20% decrease from the 6.93 days to cover calculated at the previous short interest data release.

The below chart shows the historical "days to cover" for CTIC at previous short interest release dates:

START SLIDESHOW:
Top 25 S.A.F.E. Dividend Stocks »

Loading+chart++2014+TickerTech.com

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where CTIC had been shorted as a hedge.

The chart below shows the one year performance of CTIC shares, versus its 200 day moving average. Looking at this chart, CTIC's low point in its 52 week range is $0.97 per share, with $4.25 as the 52 week high point — that compares with a last trade of $3.07.

CTI BioPharma Corp Chart

According to the ETF Finder at ETF Channel, CTIC makes up 1.00% of the SPDR S&P Biotech ETF (XBI) which is lower by about 0.1% on the day Thursday.

In afternoon trading Thursday, CTIC was up about 1% on the day.

More from Stocks

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Will Tesla Stock Tumble 33% to $195?

Will Tesla Stock Tumble 33% to $195?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump